comparemela.com

Zuma 7 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Recent Data on Axi-Cel in Lymphoma

Dr Leslie discusses two abstracts on axi-cel recently presented at ASH 2023: a subgroup analysis of ZUMA-7 and the 4-year follow-up from ZUMA-5.

Lori leslieJamesk mccloskeyGloria lesliePeer exchangeResearch programsJohn theurer cancer centerHackensack university medical centerHackensack university medicalAssociate professorIndolent lymphomaMash 2023Zuma 7Axi celLargeb cell lymphomaOlder populationCart cell therapy

Dr Leslie on the Clinical Benefit of Axi-Cel in Elderly Patients With R/R LBCL

Lori A. Leslie, MD, discusses the efficacy and safety of second-line axicabtagene ciloleucel in elderly patients with high-risk, relapsed/refractory large B-cell lymphoma.

Gloria leslieChronic lymphocytic leukemia research programsHackensack meridian school of medicineJohn theurer cancer centerIndolent lymphomaHackensack meridian schoolJohn theurer cancer centerAxi celElderly patientsZuma 7

Second-Line Axi-Cel Prolongs Survival Over SOC in Elderly Patients With R/R LBCL

The administration of axicabtagene ciloleucel in the second-line setting improved overall survival and progression-free survival vs standard-of-care treatment in patients with relapsed/refractory large B-cell lymphoma who are at least 65 years of age.

Noord hollandUnited statesMarie josAmerican society of hematologyAmsterdam university medical centersAnnual meetingAmsterdam university medicalCart cell therapyZuma 72023 ash annual meetingRelapsed refractory largeb cell lymphoma

Real-World Use of CAR T-Cell Therapy in Patients with Lymphoma

Explore the real-world application of CAR T-cell therapy in lymphoma treatment, from response rates to its role in first-line therapy.

International prognostic indexLargeb cell lymphomaB cell lymphomaCart cell therapyLymphoma treatmentResponse rateEvent free survivalDouble hit lymphomaTriple hit lymphomaZuma 7Belinda trialTransform trialAutologous stem cell transplantFirst line therapyR chopHigh risk lymphoma

Diffuse Large B-Cell Lymphoma: Moving Novel Therapy to the Frontline Setting

Expert perspectives on recent efforts to move novel therapy from the relapsed/refractory to frontline setting of diffuse large B-cell lymphoma.

Translating recent evidenceReal world managementRefractory diffuse largeb cell lymphomaLargeb cell lymphomaMoving novel therapyDiffuse largeb cell lymphomaRelapsed refractory dlbclRr dlbclL mind studyL mind trialTl mindR chopFront mindFront mind studyFront mind trialZuma 7

vimarsana © 2020. All Rights Reserved.